Non-Small-Cell Lung Carcinoma
Lung cancer is primarily classified into small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer grows and spreads more slowly than small cell lung cancer, allowing various treatments such as surgery and cancer drugs

Therapies and Market Outlook
In the U.S. and other developed countries, NSCLC population is at 710,000 now and continuously growing. The biggest share of the current NSCLC therapy market is taken by EGFR target therapies. According to UBS, Tagrisso, the latest 3rd generation EGFR targeted therapy, will rapidly grow from KRW 1.2 trillion in 2017 to KRW 6.5 trillion in 2023.
Voronoi Candidate is Different
Overcoming the EGFR Resistance Mechanism
The biggest concern in the EGFR targeted therapy market is how to overcome resistance in the lung cancer. Resistance develops after a therapy is used for some time. Tagrisso is recognized for overcoming resistance to 1st– and 2nd generation therapies. However, clinical investigations (AURA Phase 2 Extension, AURA2 Phase) have shown that even with Tagrisso, half of patients develop resistance (C797S or MET amplification) and their disease resumes progress in 12.5 months after using the drug. Voronoi’s candidate improves efficacy and delays resistance through combination with EGFR target therapies. We conducted a long-term evaluation of the lung cancer xenograft animal model. The study has confirmed that tumors disappeared in most patients in the group which used Tagrisso and Voronoi’s candidate in combination. Also, after 120 days, resistance developed in the group which used Tagrisso only, but did not in the combination-administered group.
Therapy Development Status
Clinical Trial to Begin in 2019
We plan to begin phase 1 in 2019. We are planning the details of the study with the advice of Professor Pasi A. Jänne, MD, PhD at Dana-Farber Cancer Institute (DFCI) of Harvard, who led the clinical development of Tagrisso. His advice will be helpful to effective combination study.
Market Potential
Voronoi’s candidate is expected to prolong patients’ survival through combination with Tagrisso, a 3rd generation EGFR targeted therapy. In addition, we have confirmed synergistic effect in combination with other EGFR targeted therapies. Since our candidate complements existing EGFR targeted therapies, instead of competing with them, it will have an easy access to market.
Voronoi is developing therapeutic candidate for non-small cell lung cancer and other solid cancers, by designing selective inhibitors of new kinase related to EGFR inhibitor acquired-resistance. Voronoi candidate selectively suppresses VRN6 kinase activity involved in EGFR resistance. In animal tests, we confirmed that when co-treated with existing EGFR lung cancer drugs, the xenografted tumor completely disappeared in the high-dose group, and time to tumor resistance and survival rate considerably increased in the low-dose of VRN6 group. We are investigating other EGFR inhibitor-resistant cell lines for combination therapy, with the advice from Dr. Pasi A. Jänne at DFCI, Harvard, a world-renowned expert in EGFR targeted drug development. In addition, we plan to initiate clinical trials in 2019.
(Korean) 이노엔, 보로노이서 ‘선택적 RET 저해제’ 도입…항암신약 개발 – 한국경제 BIO Insight
Sorry, this entry is only available in Korean.
보로노이, 美오릭에 폐암 치료제 7200억 기술수출
EGFR/HER2 Exon20 ins. 돌연변이 폐암 및 고형암 치료 뇌 전이암까지도 치료 가능한 정밀 표적신약 美 나스닥 상장사 ORIC에 7200억원 기술이전
(Korean) 2019 보로노이 심포지엄 성료…국내외 의학계 별들 모였다 – 한국경제
Sorry, this entry is only available in Korean.
VRN07, EGFR exon 20 insertion, Non-Small Cell Lung Cancer
Voronoi’s VRN07 program aims to treat NSCLC by targeting EGFR exon 20 insertion. Voronoi aims to also overcome brain metastasis by developing brain-permeable compound.
VRN02, DYRK1A, Autoimmune Disease
VRN02 program is under development for the treatment of autoimmune diseases, by inhibiting DYRK1A kinase activity. Series of animal experiments have suggested that VRN02 has efficacy for major autoimmune diseases such as rheumatoid arthritis, lupus, psoriasis, inflammatory bowel disease, and atopic dermatitis, and we are expanding into other indications. VRN02 is under development not only as oral pills, but also as topical formulation to apply on skin.
Scientific Advisor: Lillian L. Siu, M.D.
BMO Chair in Precision Genomics Professor of Medicine, Princess Margaret Cancer Centre, Toronto, Canada
Scientific Advisor: Pasi A. Jänne, MD, PhD
Dr. Jänne is the Director of the Lower Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School.
VRN04, RIPK1, Autoimmune diseases
VRN04 program is under development for the treatment of inflammatory diseases, by inhibiting RIPK1 kinase activity. Series of animal experiments have suggested that VRN04 has efficacy for major inflammatory diseases such as acute lung injury, rheumatoid arthritis, psoriasis, and inflammatory bowel disease, and we are expanding into other indications.
VRN06, RET, Non-Small Cell Lung Cancer
Voronoi’s VRN06 program aims to treat NSCLC by targeting RET.
VRN08, TTK, Triple-negative Breast cancer
Voronoi’s VRN08 program aims to treat TNBC by targeting TTK. We plan to expand indication to other solid tumors like pancreatic cancer and brain cancer. As TNBC, pancreatic cancer, and brain cancer are areas where existing targeted therapeutics and immuno-oncology drugs have little efficacy, development of effective and safe therapeutics is urgently needed.
VRN03, Undisclosed, Non-Small Cell Lung Cancer/Pancreatic Cancer/Head and Neck Squamous Cell Carcinoma
Voronoi’s VRN03 program aims to treat NSCLC, pancreatic cancer, and HNSCC. In the case of NSCLC, we are developing a combination therapy to delay the onset of resistance of the existing EGFR-targeted therapeutics.
VRN02, DYRK1A, Autoimmune diseases
VRN02 program is under development for the treatment of autoimmune diseases, by inhibiting DYRK1A kinase activity. Series of animal experiments have suggested that VRN02 has efficacy for major autoimmune diseases such as rheumatoid arthritis, lupus, psoriasis, inflammatory bowel disease, and atopic dermatitis, and we are expanding into other indications. VRN02 is under development not only as oral pills, but also as topical formulation to apply on skin.
VRN01, LRRK2, Glioblastoma
VRN01 program is under development for the treatment of brain tumor, especially GBM (Glioblastoma multiforme) which is known to be the most malignant form of brain tumor, by inhibiting LRRK2 kinase activity.
VRN07, EGFR exon 20 insertion. Non-Small Cell Lung Cancer
Voronoi’s VRN07 program aims to treat NSCLC by targeting EGFR exon 20 insertion. Voronoi aims to also overcome brain metastasis by developing brain-permeable compound.
Park Junil / Business Development(China and Emerging markets)
Before joining Voronoi, Mr. Park dedicated his career to Mirae Asset Private Equity Fund right after his graduation from Pecking University. Based on his 10 years of experience, he is contributing to Voronoi’s strategies for globalization and value creation.
“보로노이, 뇌연구원서 ‘우울증 치료물질 탐색 플랫폼’ 도입” -바이오스펙테이터
보로노이가 한국뇌연구원(KBRI)으로부터 뇌질환 신약개발을 위해 ‘우울증 치료물질 탐색기술’ 플랫폼을 도입했다고 20일 밝혔다.
Nathanael Gray and Eric Fischer along with Deerfield Management create new Center for Protein Degradation at DFCI
Dana-Farber Cancer Institute and Deerfield Management announced today an up to $80 million collaboration to create the Center for Protein Degradation at Dana-Farber to be led by BCMP Faculty members, Nathanael Gray and Eric Fischer,.
Molecular Modeling: a Foundation for Efficient Drug Development
A breakthrough technology that transformed the existing random and intuitive method, by making the targets and candidates for new drugs visually understandable.
Introducing Voronoi Bio
Dr. Son has developed compounds licensed out to global pharmaceuticals, and now introduces Voronoi Bio.
Brain Tumor
We are developing a new therapy targeting brain tumor stem cells, a cause of brain tumor relapse. We are working to treat GBM, or Glioblastoma, the most malignant form of brain cancer.
Alzheimer’s Disease
We are developing a therapy that targets both amyloid beta and tau.
Animal tests have proven that Voronoi’s candidate significantly suppresses them and
substantially improves cognitive function.
Chronic Inflammatory Disease
TNF- α is well known as a core cause of inflammation, accompanied by autoimmune diseases. Voronoi has identified a candidate compound that blocks signal transduction of TNF- α. We are now developing therapies for rheumatoid arthritis, inflammatory bowel disease, systemic psoriasis, xerophthalmia, macular degeneration and degenerative brain disease.
Non-Small-Cell Lung Carcinoma
We identified a candidate that can overcome the EGFR (Epidermal growth factor receptor) resistance issues existing cancer drugs had. The candidate is being developed as therapy for lung cancer and various solid cancers.
R&D Platform
We lead next-generation therapy development based on advanced technologies and platform.
Collaboration
"Voronoi endeavors to open a new chapter in tumor treatment, giving patients new hope."
Nathanael Gray, PhD
Nathanael Gray is the Nancy-Lurie Marks Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and the Dana Farber Cancer Institute.
About VORONOI
Voronoi Group consists of the parent company Voronoi and its subsidiaries Voronoi Bio and B2S Bio. Voronoi leads clinical development throughout the R&D journey. Voronoi Bio focuses on R&D of molecular modeling and kinase inhibitor, and B2S Bio focuses on TPD.
Meet the experts
Our experts and the management bring to the team years of experience and expertise in various fields.
Alzheimer’s Disease
Developing Selective Inhibitor of 「Novel Kinase」 closely related to forming of Amyloid Beta and Tau Tangle
Targeted therapy for Lung Cancer, a Challenge to Overcome Resistance
Tagrisso, known as lung cancer patients’ last hope, has only 12.5 months of response duration. Voronoi is developing combination therapies to overcome resistance, and ultimately lung cancer itself.
Developing Next-Gen Innovative Drugs
We develop first-in-class and best-in-class global innovative drugs.
“하버드 다나파버·보로노이, 신약 공동 개발을 위한 연구 계약 체결”-매일경제
국내 제약 기업 보로노이와 다나파버 암센터는 항암 신약 개발과 퇴행성 뇌질환 치료제 개발을 위한 공동연구 계약을 체결했다고 23일 밝혔다.
“美 하버드 의대 암센터 기술 이식받는다, 보로노이 490억원에 이전 계약”-중앙일보
국내 제약 기업인 보로노이㈜는 미국 하버드대학 산하 다나파버 암센터로부터 파킨슨병 치료 후보물질을 기술 이전받는 계약을 맺었다고 밝혔다.